Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 9 months later Feb 2026 → Dec 2027
See other at-risk trials from Hangzhou Broncus Medical Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Feb 2026 to Dec 2027 Show 5 more changesShow less
    • Trial status changed: Unknown → Recruiting
    • Study completion pushed from Aug 2026 to Jun 2028
    • Enrollment target: 200 to 189
    • Eligibility criteria expanded, about 38 words
    • Secondary endpoints: details revised at 3 of 8 entries
  2. Changed Registry marked status Unknown; last known: Recruiting
  3. Trial status: Not Yet Recruiting to Unknown
    • Start date changed from estimate of Apr 2023 to Jul 4, 2023
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation device.
Trial Details
NCT Number NCT05799664
Lead Sponsor Hangzhou Broncus Medical Co., Ltd.
Conditions
(from sponsor)		 COPD
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 189 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov